Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy

StatusActive, Not Recruiting
PhasePhase 1
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study completion pushed from Oct 2, 2026 to Sep 1, 2027
    • Start date: Jun 14, 2016 to Dec 28, 2015
    • Secondary endpoints: details revised at 1 of 2 entries
    • Eligibility criteria shortened, about 2 words
  2. Study completion date: Oct 31, 2025 to Oct 2, 2026v24
  3. Study completion date: Dec 31, 2024 to Oct 31, 2025v23
  4. Study completion date: Dec 31, 2023 to Dec 31, 2024v22
  5. Enrollment target: estimated 19 to confirmed 11
    • Study completion date: Dec 31, 2022 to Dec 31, 2023
    v21
Show 19 earlier versionsHide 19 earlier versions
  1. Primary completion date: Nov 30, 2017 to Dec 4, 2017
    • Study completion date: Dec 31, 2021 to Dec 31, 2022
    v20
  2. Start date: Nov 2015 to Jun 14, 2016
    • Primary completion date changed from estimate of Feb 2020 to Nov 30, 2017
    • Study completion date: Feb 2020 to Dec 31, 2021
    v19
  3. Primary and study completion dates: Feb 2019 to Feb 2020v18
  4. Re-verified, no change to tracked fieldsv17
  5. Primary and study completion dates: Apr 2018 to Feb 2019v16
  6. Trial status: Recruiting to Active, Not Recruiting
    • Start date: Nov 17, 2015 to Nov 2015
    • Site details revised
    v15
  7. Re-verified, no change to tracked fieldsv14
  8. Primary completion date: Apr 2017 to Apr 2018v13 Show 4 more changesShow less
    • Study completion date: Apr 2018
    • Start date: Nov 2015 to Nov 17, 2015
    • Secondary endpoints: details revised at 2 of 2 entries
    • Study description shortened, about 4 words
  9. Enrollment target: 12 to 19
    • Eligibility criteria expanded, about 2 words
    v12
  10. Eligibility criteria shortened, about 2 wordsv11
  11. Primary completion date: Feb 2017 to Apr 2017
    • Eligibility criteria expanded, about 53 words
    v10
  12. Trial status: Active, Not Recruiting to Recruiting
    • Primary completion date: Nov 2016 to Feb 2017
    • Site details revised
    v9
  13. 2 versions Re-verified since Mar 16, 2016, no change to tracked fieldsv7-v8
  14. Trial status: Recruiting to Active, Not Recruiting
    • Site details revised
    v6
  15. Eligibility criteria shortened, about 10 words
    • Study description expanded, about 23 words
    v5
  16. Eligibility criteria shortened, about 6 wordsv4
  17. Trial status: Not Yet Recruiting to Recruiting
    • Primary completion date: May 2017 to Nov 2016
    • Start date: May 2016 to Nov 2015
    • Site details revised
    v3
  18. Primary completion date: Oct 2016 to May 2017
    • Start date: Oct 2015 to May 2016
    v2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
City of Hope Medical Center
411 trials monitored
See 53 trials at risk
Breast Cancer
5,455 trials monitored
See 306 trials at risk
Lung Cancer
4,798 trials monitored
See 270 trials at risk
Colorectal Cancer
3,405 trials monitored
See 162 trials at risk
and 9 more diseases
This phase I trial studies the side effects of vaccine therapy and pembrolizumab in treating patients with solid tumors that have spread to other places in the body and usually cannot be cured or controlled with treatment, that have failed prior therapy, and that cannot be removed by surgery. Vaccines made from a gene-modified virus may help the body build an effective immune response to kill tumor cells. Monoclonal antibodies, such as pembrolizumab, may block tumor growth in different ways by targeting certain cells. Giving vaccine therapy together with pembrolizumab may be a better treatment in patients with solid tumors.
Trial Details
NCT Number NCT02432963
Lead Sponsor City of Hope Medical Center
Collaborators: National Cancer Institute (NCI)
Conditions
(from sponsor)		 Adult Solid Neoplasm, Bladder Carcinoma, Colon Carcinoma, Estrogen Receptor Negative, Head and Neck Squamous Cell Carcinoma, Hepatocellular Carcinoma, HER2/Neu Negative, Melanoma +9 more
Related terms Carcinoma, Hepatocellular, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Colonic Neoplasms, Melanoma, Pancreatic Neoplasms, Rectal Neoplasms, Sarcoma, Squamous Cell Carcinoma of Head and Neck, Triple Negative Breast Neoplasms, Urinary Bladder Neoplasms
Enrollment 11 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov